Healthtech startup Daye is empowering women by providing better ways to understand, monitor and improve their menstrual, hormonal and reproductive health. The company has a vision of raising the standard of gynaecological health by making it easier for women and assigned female at birth (AFAB) individuals to take care of their health. Daye aims to close the gender gap in medical research and innovation by creating convenient products and services for period pain, at-home STI testing, and the treatment of vaginal infections.
Daye has just secured about €11.5 million in new funding for its mission. The Series A investment was led by Hambro Perks, with additional participation from MassMutual Ventures and Canadian venture capital company Cross Border Impact Ventures. Leading UK health solutions provider, Simplyhealth, and UK medics Dr Michelle Tempest and Dr Fiona Pathiraja also invested in the latest funding round. The funds will be used to launch a new tampon-based at-home vaginal microbiome screening kit and roll out a digital platform for gynae health.
The tampon-based screening test provides a simple way for women to test themselves at home for vaginal infections like thrush or bacterial vaginosis (BV), and disruptions to the microbiome, which could leave them prone to a higher risk of STIs, gynaecological cancers, and fertility and IVF complications. Simplyhealth and Daye will collaborate to bring these products to market, especially via Simplyhealth’s large corporate customer base. Daye aims to reduce pain, shame and time wasted for women as they navigate their health journey from the first period through to menopause.
Daye’s funding will help the company expand to the US market as it takes on the global femtech sector, estimated to reach a market worth of €75 billion by 2025. The company has now raised about €21 million in total. Ryan Collins, Managing Director of MassMutual Ventures, expressed excitement about Daye’s success in the UK and said that the team is “raising the bar for feminine care and women’s health.”
Valentina Milanova, Founder of Daye, is delighted with the success of the funding round, which she believes is critical in helping the company build a comprehensive platform for gynae health and launch its tampon-based screening test. Tom Bradley, Partner at Hambro Perks, said that the team at Daye brings a clear passion for changing the women’s health space and is doing critical work to bridge the gender gap in innovating health technology. Daye has ambitious plans to ensure that women’s health is treated with the importance it deserves, and the company is grateful to its investors for joining them on that journey.
